ANK-101 is under clinical development by Ankyra Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ANK-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ANK-101 overview
ANK-101 is under development for the treatment of solid tumor, cutaneous, subcutaneous, soft Tissue or nodal Tumors, cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma and non-small cell lung cancer. It is administered through intratumor route. The drug candidate is a cytokine based immunotherapy. It acts by targeting IL-12.
Ankyra Therapeutics overview
Ankyra Therapeutics is working on a technology that will vastly increase the safety and efficacy of cancer cytokine immunotherapies. The company is headquartered in Boston, Massachusetts, the US.
For a complete picture of ANK-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
